Lupin Receives Approval for Sulfamethoxazole and Trimethoprim Oral Suspension USP

Wednesday January 6, 2021 at 12:36 pm

Mumbai, Baltimore, January 6, 2021: Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, from the United States Food and Drug Administration, to market a generic equivalent of Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc.

Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type).

Sulfamethoxazole and Trimethoprim Oral Suspension USP (RLD: Bactrim) had estimated annual sales of approximately USD 19 million in the U.S. (IQVIA MAT September 2020).

Releted Blog
  • Benefits of High-Intensity Interval Training workout

    In the realm of fitness, High-Intensity Interval Training (HIIT) has emerged as a revolutionary approach to exercise. This intense yet time-efficient ...

  • Everything Around Mental Wellness

    Introduction In today's fast-paced and demanding world, mental health has emerged as a critical aspect of overall well-being. The stigma surrounding ...

  • Health Benefits of Resistance Training

    In the pursuit of a healthier and more fulfilling life, exercise plays a pivotal role. Among the diverse forms of exercise, resistance training stands...